Boston Scientific Corporation

Total Valuation

Boston Scientific Corporation carries a market capitalization of 71.05B, placing it among publicly traded companies globally. Its enterprise value stands at 74.07B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Boston Scientific Corporation currently has 1.45B shares outstanding.

Valuation Ratios

Boston Scientific Corporation trades at a trailing price-to-earnings ratio of 17.19. The price-to-sales ratio is 3.01, and the price-to-book ratio stands at 2.48.

Enterprise Valuation

On an enterprise value basis, Boston Scientific Corporation trades at an EV/EBITDA multiple of 12.72 and an EV/FCF ratio of 12.63. The EV/Sales ratio of 3.53 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 16.80 provides insight into valuation relative to core operating earnings.

Financial Position

Boston Scientific Corporation maintains a current ratio of 1.24, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 50.15, indicating elevated leverage, while an interest coverage ratio of 16.04 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Boston Scientific Corporation posts a return on equity of 15.52 and a return on invested capital of 11.57.

Taxes

Over the trailing twelve months, Boston Scientific Corporation has paid 192.00M in income taxes, reflecting an effective tax rate of 4.97.

Stock Price Statistics

Boston Scientific Corporation's stock has declined approximately -55.79804% over the past 52 weeks. The 50-day moving average sits at 46.89, while the 200-day moving average is 66.76.

Income Statement

Over the trailing twelve months, Boston Scientific Corporation generated 21.00B in revenue and converted that into 3.68B in net income, yielding earnings per share of 2.46. EBITDA reached 5.82B, while operating income came in at 4.41B.

Balance Sheet

Boston Scientific Corporation holds 539.00M in cash and equivalents against 12.62B in total debt, resulting in a net debt position of 11.96B. Total book value stands at 24.93B, with working capital of 1.54B providing operational flexibility.

Cash Flow

Boston Scientific Corporation produced 4.53B in operating cash flow over the past twelve months. After subtracting -993.00M in capital expenditures, free cash flow totaled 3.54B - equivalent to 2.39 per share.

Margins

Boston Scientific Corporation operates with a gross margin of 69.92, reflecting its pricing power and cost economics. The operating margin of 21.00 and net profit margin of 17.50 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Boston Scientific Corporation's most recent stock split took place on November 6, 2003 with a 1:2 split ratio.

Scores

Boston Scientific Corporation posts an Altman Z-Score of 4.31, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.